AstraZeneca and Merck Get an FDA Priority Review for Lynparza in Prostate CancerThe Motley Fool • 01/21/20
How Does Bristol-Myers Squibb’s Revenue And Other Key Metrics Compare With That of Merck?Forbes • 01/21/20